267 related articles for article (PubMed ID: 26770651)
1. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.
Khalil HS; Langdon SP; Kankia IH; Bown J; Deeni YY
Oxid Med Cell Longev; 2016; 2016():4148791. PubMed ID: 26770651
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.
Khalil HS; Langdon SP; Goltsov A; Soininen T; Harrison DJ; Bown J; Deeni YY
Oncotarget; 2016 Nov; 7(46):75874-75901. PubMed ID: 27713148
[TBL] [Abstract][Full Text] [Related]
3. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
4. 4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling.
Chen HH; Chen YT; Huang YW; Tsai HJ; Kuo CC
Free Radic Biol Med; 2012 Mar; 52(6):1054-66. PubMed ID: 22245092
[TBL] [Abstract][Full Text] [Related]
5. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
6. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
8. Regulation of hemeoxygenase-1 gene expression by Nrf2 and c-Jun in tertiary butylhydroquinone-stimulated rat primary astrocytes.
Park JS; Kim HS
Biochem Biophys Res Commun; 2014 May; 447(4):672-7. PubMed ID: 24755082
[TBL] [Abstract][Full Text] [Related]
9. HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction.
Kang HJ; Yi YW; Hong YB; Kim HJ; Jang YJ; Seong YS; Bae I
Sci Rep; 2014 Dec; 4():7201. PubMed ID: 25467193
[TBL] [Abstract][Full Text] [Related]
10. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
11. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
[TBL] [Abstract][Full Text] [Related]
12. Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target.
Almazari I; Park JM; Park SA; Suh JY; Na HK; Cha YN; Surh YJ
Carcinogenesis; 2012 Feb; 33(2):368-76. PubMed ID: 22095074
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
14. NF-E2 related factor 2 activation and heme oxygenase-1 induction by tert-butylhydroquinone protect against deltamethrin-mediated oxidative stress in PC12 cells.
Li HY; Zhong YF; Wu SY; Shi N
Chem Res Toxicol; 2007 Sep; 20(9):1242-51. PubMed ID: 17676812
[TBL] [Abstract][Full Text] [Related]
15. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
Kulkarni S; Saju L; Farver C; Tubbs R
Int J Cancer; 2012 Nov; 131(10):2420-32. PubMed ID: 22377768
[TBL] [Abstract][Full Text] [Related]
16. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract][Full Text] [Related]
17. 7,8-Dihydroxyflavone protects human keratinocytes against oxidative stress-induced cell damage via the ERK and PI3K/Akt-mediated Nrf2/HO-1 signaling pathways.
Ryu MJ; Kang KA; Piao MJ; Kim KC; Zheng J; Yao CW; Cha JW; Chung HS; Kim SC; Jung E; Park D; Chae S; Hyun JW
Int J Mol Med; 2014 Apr; 33(4):964-70. PubMed ID: 24503931
[TBL] [Abstract][Full Text] [Related]
18. The cytoprotective effects of 7,8-dihydroxyflavone against oxidative stress are mediated by the upregulation of Nrf2-dependent HO-1 expression through the activation of the PI3K/Akt and ERK pathways in C2C12 myoblasts.
Kang JS; Choi IW; Han MH; Kim GY; Hong SH; Park C; Hwang HJ; Kim CM; Kim BW; Choi YH
Int J Mol Med; 2015 Aug; 36(2):501-10. PubMed ID: 26096841
[TBL] [Abstract][Full Text] [Related]
19. Functional dissection of Nrf2-dependent phase II genes in vascular inflammation and endotoxic injury using Keap1 siRNA.
Kim JH; Choi YK; Lee KS; Cho DH; Baek YY; Lee DK; Ha KS; Choe J; Won MH; Jeoung D; Lee H; Kwon YG; Kim YM
Free Radic Biol Med; 2012 Aug; 53(3):629-40. PubMed ID: 22609006
[TBL] [Abstract][Full Text] [Related]
20. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
